marathon06.org

[edit]

Tuesday, April 2, 2013

Yesterday, the deadline expired for the rainbow colored sidewalk located at Rainbow Oxford St, Taylor Square in Sydney, Australia to remain intact.

The pedestrian crossing had been painted with the colors of the rainbow to celebrate lesbian, gay, bisexual, and transgender community (LGBT) pride march in Sydney during this year’s Mardi Gras celebrations, at a cost of AU$11,000 and, according to a spokesman for the City of Sydney, it had a very positive impact for local tourism and within the community.

The initial idea plan was to conduct a month long pilot and, if positive, keep the crossing painted in rainbow colors for twelve month period. However, the Roads and Maritime Services (RMS) warned of the potential danger the painted the road could pose for drivers and demanded the road be painted over. Despite an online petition gathered almost 15,000 signatures to save the rainbow, the Roads Minister Duncan Gay and Premier Barry O’Farrell decided not to meet the requests from the City of Sydney for the road to remain with the colors of rainbow.

A spokeswoman for Gay’s office cited road safety hazard and unsafe behavior as the reason for removal, including people who sat in the road to take pictures. Alex Greenwich, the local representative from Sydney in the New South Wales state government, had organised the petition earlier and said Gay exaggerated the potential safety hazards, and said that people took pictures during the parade of Mardi Gras, when there was no traffic.

Sydney Lord Mayor Clover Moore also disputed Mr Gay’s claims, citing no safety hazards, “The audit also shows that generally the risk to the public of having the rainbow crossing is low. This is bureaucracy gone wild — the Minister wants to remove the crossing because he doesn’t like some pictures that people have been taking. Those pictures are a drop in the ocean compared to the tens of thousands of other pictures of the crossing that have … promoted Oxford St as one of the best LGBT tourism destinations in the world.” The walk is scheduled to be painted over this week and will cost about AU$35,000.

Wednesday, February 23, 2005A compound in the common daisy-like plant feverfew kills human leukemia stem cells and could form the basis for newer, more effective drugs for the disease.

American researchers at the University of Rochester Medical Center in New York say that it could take months to develop a useable drug from the compound, parthenolide.

However, they are working to do so with chemists at the University of Kentucky who have identified a water-soluble molecule with the same properties. The US National Cancer Institute has also accepted the work into its rapid access program, which aims to speed experimental drugs into human clinical trials.

“This research is a very important step in setting the stage for future development of a new therapy for leukemia,” says Rochester researcher Craig Jordan. “We have proof that we can kill leukemia stem cells with this type of agent, and that is good news.”

Parthenolide appears to target the roots of myeloid leukemia, stem cells, while current treatments including the relatively new drug Gleevec don’t. So, “You’re pulling the weed without getting to the root,” says Jordan.

Used for centuries to fight fevers, inflammation and arthritis, feverfew earned interest from the Rochester researchers after other scientists showed that it could prevent skin cancer in animal models.

So the researchers investigated how a concentrated form of the plant component parthenolide would affect leukemia cells and normal cells.

Comparing the impact of parthenolide to the common chemotherapy drug cytarabine, they found that parthenolide selectively killed leukemia cells while sparing normal cells better.

While the findings suggest that parthenolide is a good starting point for new drugs, people with leukemia aren’t being encouraged to take high doses of feverfew as they could not take enough of the remedy to halt the disease.

The research is reported in the journal Blood.

Friday, September 18, 2015

Mr Justice Saunders today imprisoned a man for eight years at the Old Bailey in London after an FBI sting in which he tried to buy ricin on the Dark Web.

Mohammed Ali, 31, from Liverpool, was convicted at trial of attempting to possess a chemical weapon. He told the jury he was “curious” about the Dark Web, which is a largely hidden and difficult to police section of the Internet. Ali said he didn’t realise he had done anything illegal.

Ali was prosecuted under the Chemical Weapons Act 1996 after sending an undercover agent a message reading “Hi, would you be able to make me some ricin and send it to the UK?” He bought 500mg, which has the potential to kill about 1,400, but was sent a dummy package. Counter-terror police in the UK liaised with the FBI.

The powder, which Ali paid for in BitCoin, was actually harmless. Hidden inside a toy car, the package was treated with markers and his face glowed under ultraviolet light, indicating he had handled it. The judge said today there was “real risk” involved.

Ali told his trial he had discovered drugs and guns for sale. Computer analysis showed he had looked up ricin and other poisons; he said he went for ricin simply because it had appeared in Breaking Bad. He also searched for small animals after being advised to test it on a rodent; a to-do list on his computer included “paid ricin guy” and “get pet to murder”.

Mr Justice Saunders said the case called for “a deterrent sentence”, which “will appear harsh to the defendant and his family.” “Everyone needs to know that the possession of a chemical weapon is extremely serious and long prison sentences will follow.”

Wednesday, December 7, 2016

Chemotherapy is usually associated with a collection of side effects ranging from digestive problems to hair loss, but a study published this week in Human Reproduction demonstrated that female cancer patients may find they have something in common with much younger women in one specific area — their ovaries.

Scientists from the University of Edinburgh examined donated ovarian tissue from fourteen female cancer patients, most of whom had Hodgkin lymphoma, and compared it to tissue from healthy women. They found the samples from women who had been treated with a specific chemotherapeutic regimen known as ABVD not only contained greater numbers of dormant ova — egg cells — than those from women treated with harsher regimens but also more than samples from healthy women. ABVD is named for combining several drugs known as adriamycin, bleomycin, vinblastine, and dacarbazine.

These reproductive cells were not merely more plentiful in ABVD patients. They also appeared immature, “new” in the words of lead researcher Evelyn Telfer. This challenges the conventional belief that girls are born with all the ova they will ever have and the numbers can only go down as the cells are either used up by the reproductive cycle or succumb to damage or natural aging. However, further research is needed to confirm this. The study covered relatively few patients by scientific standards, and David Albertini of the Center for Human Reproduction in New York has suggested the cells may not actually be freshly grown. Instead, they may have always been there and were merely rendered more detectable by ABVD treatment.

The ability to grow new egg cells may have significant implications for women in Western societies, many of whom postpone childbearing to establish careers, sometimes into their late thirties or forties. However, Telfer warns against making use of these findings too soon: “There’s so much we don’t know about the ovary. We have to be very cautious about jumping to clinical applications.”

The experiments had been discussed earlier this year at the annual conference of the European Society of Human Reproduction and Embryology.